Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)

Inclusion Criteria

• •Subjects must have histologically confirmed pseudomyxoma peritonei (PMP)
• •* Both low-grade mucinous carcinoma peritonei (LMCP) or high-grade mucinous carcinoma (HMCP), with or without signet ring cells as well as primary or recurrent disease, will be eligible.
• •PMP disease does not have any extra-abdominal metastases, with the exception of pulmonary involvement (nodal, parenchymal, and pleural).
• •PMP disease is extensive and not amenable to operative management, with or without liver, pancreas, stomach, or abdominal wall involvement.
• •* Definition of Non-Resectable Disease-
• •* Non-resectable PMP disease will be defined as the presence of at least one of the following conditions:
• •* 1\) Extensive small bowel serosa involvement, where it is not possible to preserve at least 1.5-2 m of small bowel
• •* 2\) Extensive infiltration of the pancreatic surface
• •* 3\) Mesenteric involvement causing retraction
• •* 4\) Need for complete gastric resection
• •* 5\) Urete1ic obstruction
• •* 6\) Liver disease with no chance to achieve R0 resection with liver remnant volume \> 30%
• •* 7\) Recurrent disease not amenable to further resection
• •Subjects do not have any other available curative treatment options.
• •* Subjects can have previous abdominal operations, including CRS+HIPEC.
• •Age ≥ 18 and ≤ 75.
• •* Pediatric participants were excluded as PMP is a disease that affects adults. Participants \> 75 years of age are excluded as they are beyond the commonly accepted transplantability criteria.
• •Performance status ECOG ≤ 1.
• •Subjects must have the ability to understand and the willingness to sign a written informed consent document.